Get the Stockscreener App
21.11
0.85%
-0.18
Pre-market:
21.85
0.74
+3.51%
Vera Therapeutics Inc stock is traded at $21.11, with a volume of 922.33K.
It is down -0.85% in the last 24 hours and down -22.05% over the past month.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
See More
Previous Close:
$21.29
Open:
$21.13
24h Volume:
922.33K
Relative Volume:
1.01
Market Cap:
$1.37B
Revenue:
-
Net Income/Loss:
$-107.85M
P/E Ratio:
-9.552
EPS:
-2.21
Net Cash Flow:
$-106.82M
1W Performance:
-1.81%
1M Performance:
-22.05%
6M Performance:
-48.37%
1Y Performance:
-44.45%
1-Day Range:
$20.84
$21.90
1-Week Range:
$20.59
$21.90
52-Week Range:
$18.53
$51.61
Vera Therapeutics Inc Stock (VERA) Company Profile
Name
Vera Therapeutics Inc
Sector
Industry
Phone
650-770-0077
Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
21.11 | 1.37B | 0 | -107.85M | -106.82M | -2.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Jan-28-25 | Initiated | Goldman | Buy |
| Nov-21-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-25-24 | Initiated | Oppenheimer | Outperform |
| Jan-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-23 | Initiated | Raymond James | Outperform |
| Nov-10-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-16-23 | Initiated | Guggenheim | Buy |
| Jan-04-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-04-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-12-22 | Initiated | JP Morgan | Overweight |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-22 | Initiated | Wedbush | Outperform |
View All
Vera Therapeutics Inc Stock (VERA) Latest News
When (VERA) Moves Investors should Listen - news.stocktradersdaily.com
Alliancebernstein L.P. Boosts Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics (VERA) Stock Sees After-Market Boost - Stocks Telegraph
Wellington Management Group LLP Trims Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by JPMorgan Chase & Co. - Defense World
Polycythemia Vera Market to Show Remarkable Growth Trends from - openPR.com
Polycythemia Vera Therapeutics Market Set to Witness - openPR.com
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch - Yahoo Finance
Vanguard Group Inc. Acquires 369,387 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Corebridge Financial Inc. - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of “Buy” from Analysts - Defense World
KLP Kapitalforvaltning AS Makes New Investment in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics completes enrollment for IgAN drug trial By Investing.com - Investing.com South Africa
Vera Therapeutics stock hits 52-week low at $21.44 By Investing.com - Investing.com South Africa
Vera Therapeutics stock hits 52-week low at $21.44 - Investing.com India
Vera Therapeutics completes enrollment for IgAN drug trial - Investing.com Australia
Vera Therapeutics completes enrollment in ORIGIN Phase 3 trial for atacicept - TipRanks
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN - GlobeNewswire
Is Vera Therapeutics Inc (VERA) a threat to investors? - uspostnews.com
Teacher Retirement System of Texas Acquires 3,942 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics (NASDAQ:VERA) Reaches New 1-Year LowWhat's Next? - MarketBeat
69,724 Shares in Vera Therapeutics, Inc. (NASDAQ:VERA) Bought by Raymond James Financial Inc. - Defense World
Vera Therapeutics stock hits 52-week low at $25.97 By Investing.com - Investing.com South Africa
Vera Therapeutics stock hits 52-week low at $25.97 - Investing.com
Vera Therapeutics validates Fair Value bearish call with 42% decline By Investing.com - Investing.com UK
Swiss National Bank Purchases 15,700 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Relative Strength Alert For Vera Therapeutics - Nasdaq
AlphaQuest LLC Takes Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Acquires 7,895 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Is Vera Therapeutics (NASDAQ:VERA) Weighed On By Its Debt Load? - simplywall.st
Victory Capital Management Inc. Increases Stake in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of “Buy” by Analysts - Defense World
Vera Therapeutics (VERA) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Vera Therapeutics Growth Accelerates: 9 Strategic Hires Secure Equity Package Worth $2.3M - StockTitan
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MENAFN.COM
What is HC Wainwright’s Estimate for VERA FY2025 Earnings? - Defense World
Vera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much? - Seeking Alpha
Cantor Fitzgerald Analysts Lower Earnings Estimates for VERA - Defense World
JPMorgan Chase & Co. Has Lowered Expectations for Vera Therapeutics (NASDAQ:VERA) Stock Price - Defense World
Vera Therapeutics (NASDAQ:VERA) Price Target Cut to $71.00 by Analysts at JPMorgan Chase & Co. - Armenian Reporter
Vera Therapeutics Getting Closer To Key Technical Benchmark - MSN
Rhumbline Advisers Has $2.48 Million Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Q1 EPS Estimates for Vera Therapeutics Boosted by Wedbush - Defense World
(VERA) On The My Stocks Page - news.stocktradersdaily.com
What is Wedbush’s Forecast for VERA FY2029 Earnings? - Defense World
Guggenheim Raises Vera Therapeutics (NASDAQ:VERA) Price Target to $61.00 - Defense World
Vera Therapeutics Inc Stock (VERA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):